宜宾韩式双眼皮整形美容医院(宜宾哪个专家做双眼皮好) (今日更新中)

The Girl Scouts of the USA revealed on Tuesday that a French-toast inspired cookie is coming in 2021.In a press release, the organization said the "Toast-Yay!" cookie, which is "dipped in delicious icing and full of flavor in every bite," will be available in select areas sometime next year.In March, due to the coronavirus pandemic, the organization switched to online sales.According to the release, the 2021 cookie season will again turn to sell cookies online and through "virtual cookie booths" on social media."Many girls will offer socially distant or contactless sales and delivery options," the Girl Scouts said in the release. "If local guidelines allow, in-person sales may also be available in certain areas, keeping girls’ safety top priority."The start of the yearly cookie season is typically in January. Still, the organization said the timing and product availability could vary, but you can check your local area to see about a specific cookie. 971

The chairman of the House Judiciary Committee subpoenaed the Justice Department on Thursday seeking documents related to a trio of recent controversial decisions made by the FBI, including the decision in 2016 to not charge Hillary Clinton after the probe of her email server and the internal recommendation by an FBI office to fire former FBI Deputy Director Andrew McCabe, his office announced.The move by Virginia Republican Bob Goodlatte represents a ratcheting up of his investigation, led jointly with the House Oversight Committee, into the decisions made by the Justice Department and the FBI before the 2016 election -- an investigation that has stoked mistrust of the law enforcement agency and drawn the ire of Democrats on Capitol Hill.In a letter to Deputy Attorney General Rosenstein accompanying the subpoena, Goodlatte wrote, "given the Department's ongoing delays in producing these documents, I am left with no choice but to issue the enclosed subpoena to compel production of these documents."Goodlatte had in recent weeks voiced his frustration at the Justice Department's refusal to comply with his past requests for the documents and hinted at the weighty legal maneuver.The two committees had requested 1.2 million pages of documents from the Justice Department, Goodlatte's office said. There are approximately 30,000 documents thought to be responsive to the committee's request, and agency staff are reviewing the remaining items to ensure they do not contain sensitive information or conflict with ongoing law enforcement actions, according to Justice Department spokesman Ian Prior.Prior said 3,000 documents have been delivered to the House Judiciary Committee so far.The subpoena issued Thursday covers documents related to "charging decisions in the investigation surrounding former Secretary Clinton's private email server in 2016," as well potential abuses of the Foreign Intelligence Surveillance Act and "all documents and communications relied upon by FBI's Office of Professional Responsibility in reaching its decision to recommend the dismissal of former Deputy Director McCabe."In a statement, Prior said, "The Department of Justice and the FBI take the Committee's inquiry seriously and are committed to accommodating its oversight request in a manner consistent with the Department's law enforcement and national security responsibilities."More than two dozen FBI staff have been assisting the Justice Department in producing documents on a rolling basis to the committee's "broad request," Prior said. 2552

The Food and Drug Administration (FDA) has cleared the way for a generic version of EpiPen to be created.The FDA’s approval for a generic version, which will be created by Teva Pharmaceuticals, could help alleviate issues like high cost for the life-saving allergy medication.Two year ago, prices for EpiPens skyrocketed, as manufacturer Mylan raised rates from less than 0 for a two-pack to close to 0.But new action by the FDA paves the way for a generic form of the drug, so pharmacies can now offer a generic form to customers, without having to call the doctor to write a new prescription."Oh, it's a huge deal for consumers because the current price is astronomical for a drug that you hope never to use,” says Gerard Anderson, a professor at Johns Hopkins University who has testified about drug prices before Congress.EpiPens have been experiencing shortages, made even worse by the back-to-school orders placed by parents. Anderson says this move to create generic forms should help with the supply and bring prices down.“You’re still gonna get the same drug administered,” says Anderson of the generic forms of the medication. “And so, as a consumer, as a parent, I would choose a less expensive alternative.” 1233

The excitement of two COVID-19 vaccines with more than 90 percent efficacy is undeniable.In November, both Pfizer and Moderna announced its scientists had developed vaccines with efficacy at or near 95 percent, but scientists are warning these vaccines are not the "silver bullet" to ending the pandemic.“We don’t want to give the public the impression that there’s an emergency use authorization and these vaccines become available in a small amount in December and we can go back to our pre-pandemic behavior,” said William Moss, executive director of the International Vaccine Access Center at Johns Hopkins.In June, the FDA released its vaccine guidelines, saying it would consider emergency use authorization for any vaccine testing with at least 50 percent effectiveness, so there is a reason for celebration, according to Moss, but only after certain questions about the vaccine are answered.Dr. Anthony Fauci has said the initial vaccines will prevent symptoms in those who become infected, rather than kill the virus itself. Moss says that means immunized people might be able to spread COVID-19 to others.He also wonders how long immunization will last. One year? Three years? Will booster doses be needed? They're all careful considerations that will only emerge once one is put into play, according to Moss.“It’s obviously tragic that the [COVID] cases are occurring that quickly, but it does help a vaccine trial because otherwise you just have to wait that much longer for samples to come in,” said Moss.The vaccine process has innovated how scientists and researchers approach these types of situations, however, according to Moss.In traditional vaccines, a small dose of the virus is injected into the body so the immune system can create antibodies. In the COVID-19 vaccine, though, both Moderna and Pfizer have used what is called messenger RNA (mRNA) where the virus’ genetic code is injected into the body so it can instruct cells on what antibodies to produce. Scientists say this way is faster, safer, and can create a stronger immune response as people are not exposed to the virus.“I suspect that if this all goes well and these vaccines are safe and continue to demonstrate 90 to 95 percent efficacy, we’re going to see other vaccines of a similar type,” said Moss. 2298

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee has endorsed Pfizer’s coronavirus vaccine, in a major step toward an epic vaccination campaign that could finally conquer the outbreak. The group, in a 17-4 vote with one abstention, concluded that the shot appears safe and effective against the coronavirus in people 16 and older.The Food and Drug Administration is expected to follow the recommendation issued Thursday by its expert advisers. A final FDA decision is expected within days. The vaccine had already been authorization by officials in Canada and the UK.An emergency use authorization allows practitioners to administer a vaccine despite it not gaining full FDA approval. The EUA means that the vaccine is allowed to be used in non-clinical settings, which would allow Americans not in a trial or hospital setting to get the vaccine.Millions of shots would then ship to begin vaccinating health care workers and nursing home residents, but the Centers for Disease Control and Prevention will need to formally recommend the vaccine before health care officials can begin distributing the shots.Once it is authorized, it is expected that several million doses of the vaccine will immediately begin being distributed throughout the US to high-risk individuals. The first group of those expected to be inoculated includes health care workers and those who live or work in assisted living facilities.“The FDA recognizes that transparency and dialogue are critical for the public to have confidence in COVID-19 vaccines. I want to assure the American people that the FDA’s process and evaluation of the data for a potential COVID-19 vaccine will be as open and transparent as possible,” said FDA Commissioner Stephen M. Hahn, M.D. “The FDA has been preparing for the review of EUAs for COVID-19 vaccines for several months and stands ready to do so as soon as a EUA request is submitted. While we cannot predict how long the FDA’s review will take, the FDA will review the request as expeditiously as possible, while still doing so in a thorough and science-based manner, so that we can help make available a vaccine that the American people deserve as soon as possible.”Pfizer says that the vaccine is showing a 95% efficacy against coronavirus infection. It is one of two vaccines that could be approved by the FDA in the next few weeks. Moderna also has a vaccine candidate that is showing the efficacy of 95%.“Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally. Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible.”One concern over the Pfizer vaccine is possible side effects on those prone to allergic reactions. The UK’s National Health Service is advising those prone to allergic reactions to not take the Pfizer vaccine as it investigates two health care workers having apparent reactions after receiving the vaccine.Once given authorization, officials will be forced to confront two challenges: Public confidence in the vaccine and distribution. Both the Moderna and Pfizer vaccines are required to be refrigerated until use, complicating distribution methods.Also, polls are showing that a significant number of Americans are hesitant to take the vaccine. Public health experts say getting the vast majority of Americans immunized is important in order to reach herd immunity against the virus and to allow for normalcy to return to the US.In addition to a number of public health experts saying they’ll get the vaccine as a way to instill trust, former Presidents Bill Clinton, George W. Bush, and Barack Obama said they would publicly take the vaccine in order to instill faith in the shot.Widespread access to the general public is not expected until the spring. 4342

来源：资阳报